Polycyclic aromatic hydrocarbons and cannabinoids in secondhand cannabis smoke.

Polycyclic aromatic hydrocarbons and cannabinoids in secondhand cannabis smoke.

CED Clinical Relevance  #62Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely.
🔬 Evidence Watch  |  CED Clinic
Journal Environment international
Study Type Clinical Study
Population Human participants
Why This Matters

This item covers developments relevant to cannabis medicine and clinical practice. Clinicians monitoring evidence in this area should review the source material.

Clinical Summary

The legalization of cannabis is exposing more people to secondhand smoke (SHS) generated during cannabis use. Given the serious health effects caused by tobacco SHS, there is a need to assess the potential health effects of exposure to cannabis SHS. As a step toward this, we measured the concentrations of cannabinoids, nicotine and polycyclic aromatic hydrocarbons (PAHs) in air samples collected in public places where cannabis was being consumed. These were compared with concentrations in exhaled aerosols from cannabis smoking and vaping, and in tobacco SHS. Tetrahydrocannabinol concentrations were 22 to 255ย ยตg/m

Dr. Caplan’s Take

“This is a development worth tracking. The clinical implications will become clearer as more evidence accumulates.”

Clinical Perspective
🧠 Clinicians should review this item in the context of their current practice and patient population.

💬 Join the Conversation

Have a question about how this applies to your situation? Ask Dr. Caplan →

Want to discuss this topic with other patients and caregivers? Join the forum discussion →

FAQ

This study item was assembled from normalized source metadata and pipeline scoring.







Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance